Guardant Health (NASDAQ:GH) CEO Amirali Talasaz Sells 143,028 Shares

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the sale, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. This trade represents a 7.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The stock was sold at an average price of $150.79, for a total transaction of $17,638,207.88.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The shares were sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Price Performance

NASDAQ:GH traded down $3.71 during mid-day trading on Tuesday, hitting $150.03. 3,327,903 shares of the company’s stock were exchanged, compared to its average volume of 2,298,095. The company has a market cap of $19.89 billion, a PE ratio of -44.26 and a beta of 1.61. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $153.95. The business has a fifty day moving average price of $113.99 and a 200 day moving average price of $104.38.

Institutional Investors Weigh In On Guardant Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. World Investment Advisors bought a new position in shares of Guardant Health during the fourth quarter valued at $1,664,000. Segall Bryant & Hamill LLC lifted its stake in Guardant Health by 57.8% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after acquiring an additional 111,822 shares during the period. TD Asset Management Inc lifted its stake in Guardant Health by 16.1% during the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after acquiring an additional 26,210 shares during the period. Algert Global LLC boosted its holdings in shares of Guardant Health by 169.1% during the 3rd quarter. Algert Global LLC now owns 120,114 shares of the company’s stock valued at $7,505,000 after acquiring an additional 75,474 shares during the last quarter. Finally, Iron Triangle Partners LP boosted its holdings in shares of Guardant Health by 33.3% during the 3rd quarter. Iron Triangle Partners LP now owns 400,000 shares of the company’s stock valued at $24,992,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Piper Sandler set a $127.00 price target on Guardant Health in a research note on Thursday, May 21st. Sanford C. Bernstein assumed coverage on Guardant Health in a report on Friday. They issued an “outperform” rating and a $175.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Mizuho raised their price target on Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Finally, The Goldman Sachs Group began coverage on Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $144.82.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.